Migdal Insurance & Financial Holdings Ltd. Has $111,000 Holdings in AbbVie Inc. (NYSE:ABBV)

Migdal Insurance & Financial Holdings Ltd. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 73.9% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 532 shares of the company's stock after selling 1,504 shares during the period. Migdal Insurance & Financial Holdings Ltd.'s holdings in AbbVie were worth $111,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. EnRich Financial Partners LLC increased its holdings in AbbVie by 196.4% in the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after buying an additional 110 shares during the period. Abound Financial LLC acquired a new position in AbbVie in the first quarter valued at approximately $30,000. Prudent Man Investment Management Inc. acquired a new position in AbbVie in the fourth quarter valued at approximately $32,000. Siemens Fonds Invest GmbH lifted its holdings in AbbVie by 197.6% in the fourth quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock valued at $32,000 after acquiring an additional 119,141 shares during the period. Finally, Pinney & Scofield Inc. acquired a new position in AbbVie in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

ABBV traded down $2.14 during midday trading on Friday, reaching $189.26. 5,331,983 shares of the company's stock were exchanged, compared to its average volume of 6,326,641. AbbVie Inc. has a one year low of $163.81 and a one year high of $218.66. The business has a 50-day simple moving average of $187.17 and a two-hundred day simple moving average of $189.38. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $334.31 billion, a price-to-earnings ratio of 80.54, a price-to-earnings-growth ratio of 1.25 and a beta of 0.48.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The company had revenue of $13.34 billion during the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter in the previous year, the company posted $2.31 earnings per share. AbbVie's quarterly revenue was up 8.4% compared to the same quarter last year. As a group, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date is Tuesday, July 15th. AbbVie's dividend payout ratio is currently 279.15%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ABBV shares. Evercore ISI boosted their price objective on AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Cantor Fitzgerald assumed coverage on AbbVie in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price target for the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $194.00 price target on shares of AbbVie in a research report on Tuesday, April 8th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, BNP Paribas upgraded AbbVie to a "hold" rating in a research report on Thursday, May 8th. Eight equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $211.29.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.